Sign in to view content

Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

Robert L. Avery, MD

Video
Published 2021

Related

Episode 201: AMD Drug Updates with Dr. Allen Ho, including Gene Therapy
Jayanth Sridhar, MD
Member Podcasts
2019
Assessing Supplemental Injection Use Across Groups in the Phase 2 DAVIO 2 Trial of EYP-1901 vs Aflibercept in Wet Age-Related Macular Degeneration
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2024
Phase 3 Randomized, Double-Masked Studies of Brolucizumab Versus Aflibercept in nAMD: Expanded Primary and Secondary Outcomes From HAWK/HARRIER
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2018

Category: AMD-Neovascular

See more